Results from Phase II clinical trials show that antibodies targeting PD-L1 in combination with PARPis exhibit a good response against germline BRCA1/2-mutated breast cancer and ovarian cancers [67,68]. This evidence concerns the gene CD274 and ovarian carcinoma.